Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

被引：0
|
作者：
Charlotte C. van Ruiten
Mark M. Smits
Megan D. Kok
Erik H. Serné
Daniël H. van Raalte
Mark H. H. Kramer
Max Nieuwdorp
Richard G. IJzerman
机构：
[1] Diabetes Center,Department of Internal Medicine
[2] Amsterdam University Medical Center,Department of Vascular Medicine
[3] Location VU University Medical Center,Department of Vascular Medicine
[4] Amsterdam University Medical Center,Department of Internal Medicine
[5] Location VU University Medical Center,undefined
[6] Amsterdam University Medical Center,undefined
[7] Location AMC,undefined
[8] Amsterdam Diabetes Center,undefined
[9] Amsterdam University Medical Centers (Amsterdam UMC),undefined
[10] Location VU University Medical Center (VUMC),undefined
来源：
Cardiovascular Diabetology | / 21卷
关键词：
SGLT2 inhibitor; Dapagliflozin; GLP-1 receptor agonist; Exenatide; Type 2 diabetes; Blood pressure; Autonomic balance; Hemodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial
    Zhang, Jie
    Xian, Tong-Zhang
    Wu, Ming-Xiao
    Li, Chen
    Wang, Weihao
    Man, Fuli
    Zhang, Xianbo
    Wang, Xiaoxia
    Pan, Qi
    Guo, Lixin
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (07) : 1529 - 1535
  • [22] Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial
    Homayouni, Fatemeh
    Haidari, Fatemeh
    Hedayati, Mehdi
    Zakerkish, Mehrnoosh
    Ahmadi, Kambiz
    PHYTOTHERAPY RESEARCH, 2018, 32 (06) : 1073 - 1079
  • [23] Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months
    Beck-Nielsen, H
    Hanefeld, M
    Komajda, M
    Dargie, H
    Curtis, P
    Zambanini, A
    Home, PD
    DIABETOLOGIA, 2005, 48 : A279 - A279
  • [24] Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes
    Barkhordarian, Maryam
    Triplitt, Curtis L.
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Cersosimo, Eugenio
    DIABETES, 2022, 71
  • [25] Effect of exenatide and dapagliflozin combination on non-alcoholic fatty liver disease in type 2 diabetes
    Guja, C.
    Repetto, E.
    Hardy, E.
    Jabbour, S. A.
    Ferranini, E.
    Gastadelli, A.
    DIABETOLOGIA, 2019, 62 : S91 - S91
  • [26] Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
    Jabbour, Serge A.
    Frias, Juan P.
    Guja, Cristian
    Hardy, Elise
    Ahmed, Azazuddin
    Ohman, Peter
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1515 - 1519
  • [27] Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
    van Ruiten, Charlotte C.
    Veltman, Dick J.
    Wijdeveld, Madelief
    Ten Kulve, Jennifer S.
    Kramer, Mark H. H.
    Nieuwdorp, Max
    IJzerman, Richard G.
    DIABETES OBESITY & METABOLISM, 2022, 24 (08): : 1588 - 1597
  • [28] Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes Study protocol of a randomized controlled trial
    Yin, Dong
    Hui, Yuan
    Yang, Chuanhui
    Xu, Yi
    MEDICINE, 2020, 99 (41) : E22660
  • [29] BLOOD PRESSURE LOWERING WITH FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE PREVENTS DEATH AND VASCULAR EVENTS IN TYPE 2 DIABETES: THE ADVANCE TRIAL
    Chalmers, J.
    Patel, A.
    MacMahon, S.
    Neal, B.
    Harrap, S. B.
    Cooper, M.
    HYPERTENSION, 2008, 52 (01) : 166 - 166
  • [30] Renoprotective effects of blood pressure lowering with perindopril-indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial
    De Galan, Bastiaan E.
    Ninomiya, Toshiharu
    Perrovic, Vlado
    Pillai, Avinesh
    Patel, Anushka
    Neal, Alan Cass Bruce
    Mogensen, Carl-Erik
    Marre, Michel
    Harrap, Stephen
    Poulter, Neil
    Cooper, Mark
    Hamet, Pavel
    Macmahon, Stephen
    Chalmers, John
    DIABETES, 2008, 57 : A218 - A219
12345